PositoAI/ US/ Pulmatrix, Inc.

Pulmatrix, Inc.

NasdaqCM: PULM · Healthcare

Positivity Index

#2,363 / 6,774

Global

#732 / 4,000

United States

Positivity Score

21,592

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Pulmatrix, Inc. — Overview & Financial Snapshot

Pulmatrix, Inc. (NasdaqCM: PULM) is a Healthcare company, ranked #2,363 of 6,774 companies globally and #732 of 4,000 in United States on PositoAI, with a Positivity Score of 21,592. Its market capitalisation is ₹48.95 Cr ($5.19M), P/E ratio is -1.3 and P/B ratio is 2.03. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.

P/B Ratio 2.03

P/E Ratio -1.3

D/E Ratio 0.00

ROE -98.35%

Owes vs Owns ? 0.21× Low $0.21 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-103.83$-1.10

Forward EPS ₹-424.76$-4.50

Beta 1.93

Market Cap ₹48.95 Cr$5.19M

What these numbers mean →

What does Pulmatrix, Inc. do?

What is Pulmatrix, Inc.'s P/E and P/B ratio?

Pulmatrix, Inc. has a P/E ratio of -1.3 and a P/B ratio of 2.03.

What is Pulmatrix, Inc.'s debt-to-equity ratio?

Pulmatrix, Inc. has a debt-to-equity ratio of 0.00.

How much does Pulmatrix, Inc. owe compared with what it owns?

Pulmatrix, Inc. owes $0.21 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Pulmatrix, Inc.'s Positivity rank?

Pulmatrix, Inc. is ranked #2,363 of 6,774 companies globally and #732 of 4,000 in United States on PositoAI, with a Positivity Score of 21,592.

Does Pulmatrix, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Pulmatrix, Inc..

Where can I read the latest news about Pulmatrix, Inc.?

Recent headlines about Pulmatrix, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Pulmatrix, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Pulmatrix, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.